![](/images/graphics-bg.png)
Autoantigen TRIM21Ro52 as a Possible Target for Treatment of Systemic Lupus Erythematosus
Joint Authors
Ozato, Keiko
Yoshimi, Ryusuke
Ishigatsubo, Yoshiaki
Source
International Journal of Rheumatology
Issue
Vol. 2012, Issue 2012 (31 Dec. 2012), pp.1-11, 11 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2012-06-04
Country of Publication
Egypt
No. of Pages
11
Main Subjects
Abstract EN
Systemic lupus erythematosus (SLE) is a chronic, systemic, and autoimmune disease, whose etiology is still unknown.
Although there has been progress in the treatment of SLE through the use of glucocorticoid and immunosuppressive drugs, these drugs have limited efficacy and pose significant risks of toxicity.
Moreover, prognosis of patients with SLE has remained difficult to assess.
TRIM21/Ro52/SS-A1, a 52-kDa protein, is an autoantigen recognized by antibodies in sera of patients with SLE and Sjögren's syndrome (SS), another systemic autoimmune disease, and anti-TRIM21 antibodies have been used as a diagnostic marker for decades.
TRIM21 belongs to the tripartite motif-containing (TRIM) super family, which has been found to play important roles in innate and acquired immunity.
Recently, TRIM21 has been shown to be involved in both physiological immune responses and pathological autoimmune processes.
For example, TRIM21 ubiquitylates proteins of the interferon-regulatory factor (IRF) family and regulates type I interferon and proinflammatory cytokines.
In this paper, we summarize molecular features of TRIM21 revealed so far and discuss its potential as an attractive therapeutic target for SLE.
American Psychological Association (APA)
Yoshimi, Ryusuke& Ishigatsubo, Yoshiaki& Ozato, Keiko. 2012. Autoantigen TRIM21Ro52 as a Possible Target for Treatment of Systemic Lupus Erythematosus. International Journal of Rheumatology،Vol. 2012, no. 2012, pp.1-11.
https://search.emarefa.net/detail/BIM-493047
Modern Language Association (MLA)
Yoshimi, Ryusuke…[et al.]. Autoantigen TRIM21Ro52 as a Possible Target for Treatment of Systemic Lupus Erythematosus. International Journal of Rheumatology No. 2012 (2012), pp.1-11.
https://search.emarefa.net/detail/BIM-493047
American Medical Association (AMA)
Yoshimi, Ryusuke& Ishigatsubo, Yoshiaki& Ozato, Keiko. Autoantigen TRIM21Ro52 as a Possible Target for Treatment of Systemic Lupus Erythematosus. International Journal of Rheumatology. 2012. Vol. 2012, no. 2012, pp.1-11.
https://search.emarefa.net/detail/BIM-493047
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-493047